Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

about

Risk of renal events following intravenous iodinated contrast material administration among inpatients admitted with cancer a retrospective hospital claims analysis

P2860

Q58707415-3D2AF385-3C07-4046-8348-359259993575

P2860

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

Item

http://www.wikidata.org/entity/Q48290381

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

@en

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

@nl

type

Item

label

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

@en

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

@nl

prefLabel

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

@en

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

@nl

P1476

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

@en

P2093

Anna Antenucci

http://www.w3.org/2001/XMLSchema#string

Anna F Pozzi

http://www.w3.org/2001/XMLSchema#string

Annunziata di Turi

http://www.w3.org/2001/XMLSchema#string

Carlo E Neumaier

http://www.w3.org/2001/XMLSchema#string

Elisabetta de Lutio di Castelguidone

http://www.w3.org/2001/XMLSchema#string

Felice Musicco

http://www.w3.org/2001/XMLSchema#string

Giovanni Cigliana

http://www.w3.org/2001/XMLSchema#string

Giulia Orlandi

http://www.w3.org/2001/XMLSchema#string

Massimo Bellomi

http://www.w3.org/2001/XMLSchema#string

Mauro Caterino

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting.

Functional contrast-enhanced CT for evaluation of acute ischemic stroke does not increase the risk of contrast-induced nephropathy.

Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis.

Contrast-induced nephropathy: definition, epidemiology, and patients at risk.

Comparison of allergic adverse effects and contrast enhancement between iodixanol and iopromide

Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center

Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material.

Incidence and outcomes of contrast-induced AKI following computed tomography.

Improving outcomes of acute kidney injury: report of an initiative.

Iodixanol: risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations.

P304

2572-2580

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCP.26132

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

233

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28777459

http://www.w3.org/2001/XMLSchema#string

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

about

P2860

P2860

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698